From SNPedia
| Geno
|
Mag
|
Summary
|
| (A;A)
|
2.1
|
poor metabolizer of several commonly prescribed drugs
|
| (A;G)
|
2
|
carrier
|
| (G;G)
|
0
|
normal
|
rs4986893 is a SNP in the
CYP2C19 gene, potentially encoding the CYP2C19*3 variant. This variant has been linked to poor metabolism of compounds like mephenytoin as well as
proguanil, and it therefore has implications for
malaria prophylaxis. [
PMID 7969038,
PMID 9093256]
The risk allele is rs4986893(A).
As a nonfunctioning CYP2C19, this variant would be expected to be a poor metabolizer of several commonly prescribed drugs, including anti-ulcer drugs like omeprazole (trade names Losec and Prilosec), esomeprazole (trade name Nexium), and lansoprazole (Prevacid).
| PharmGKB | PA162363761 |
| Name | CYP2C19*3, CYP2C19:G636A |
| Annotation | Subjects who had previously experienced myocardial infarction and were receiving clopidogrel were almost twice as likely to experience a subsequent cardiovascular event if they carried any two CYP2C19 loss-of-function alleles (CYP2C19*2, CYP2C19*3, CYP2C19*4 or CYP2C19*5) relative to those with none. Patients from this study who underwent percutaneous coronary intervention and carried two CYP2C19 loss-of-function alleles had a 3.58 times greater risk of cardiovascular events as those with none. These results suggest that treatment with clopidogrel is less effective in individuals who are homozygous for CYP2C19 loss-of-function alleles than in those who do not carry CYP2C19 loss-of-function alleles. |
| Gene | CYP2C19 |
| Featue | Exon/NonSyn |
| Evidence | PubMed ID:19106083 |
| Drugs | clopidogrel |
| Diseases | Cardiovascular Diseases, Death, Myocardial Infarction, Stroke |
| Curation Level | Curated |
[PMID 21247447] CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population
